+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opioid Dependence - Pipeline Insight, 2020

  • PDF Icon

    Clinical Trials

  • 106 Pages
  • February 2020
  • Region: Global
  • DelveInsight
  • ID: 4989224
Opioid Dependence Overview

Opioid Dependence Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Opioid Dependence market. A detailed picture of the Opioid Dependence pipeline landscape is provided, which includes the disease overview and Opioid Dependence treatment guidelines. The assessment part of the report embraces in-depth Opioid Dependence commercial assessment and clinical assessment of the Opioid Dependence pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Dependence collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Opioid Dependence of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Opioid Dependence with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Opioid Dependence treatment.
  • Opioid Dependence key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Opioid Dependence market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Opioid Dependence Analytical Perspective

In-depth Opioid Dependence Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Opioid Dependence Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Opioid Dependence report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Opioid Dependence across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Opioid Dependence therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Opioid Dependence research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Opioid Dependence .

Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Opioid Dependence .
  • In the coming years, the Opioid Dependence market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Opioid Dependence R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Opioid Dependence treatment market. Several potential therapies for Opioid Dependence are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Opioid Dependence market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Opioid Dependence ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions
  • What are the current options for Opioid Dependence treatment?
  • How many companies are developing therapies for the treatment of Opioid Dependence?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Opioid Dependence?
  • How many Opioid Dependence emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Opioid Dependence?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Opioid Dependence market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Opioid Dependence?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Opioid Dependence therapies?
  • What are the clinical studies going on for Opioid Dependence and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Opioid Dependence?
  • How many patents are granted and pending for the emerging therapies for the treatment of Opioid Dependence?

Table of Contents

1. Report Introduction
2. Opioid Dependence
2.1. Overview
2.2. History
2.3. Opioid Dependence Symptoms
2.4. Causes
2.6. Opioid Dependence Diagnosis
2.6.1. Diagnostic Guidelines
3. Opioid Dependence Current Treatment Patterns
3.1. Opioid Dependence Treatment Guidelines
4. Opioid Dependence - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Opioid Dependence companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary
4.1.2. Opioid Dependence Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Opioid Dependence Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA Assessment by Stage and MOA
5.1.6. Assessment by Target Assessment by Stage and Target
6. Opioid Dependence Late Stage Products (Phase-III)7. Opioid Dependence Mid Stage Products (Phase-II)8. Early Stage Products (Phase-I)9. Pre-clinical Products and Discovery Stage Products10. Inactive Products11. Dormant Products12. Opioid Dependence Discontinued Products
13. Opioid Dependence Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description Product Overview Mechanism of action
13.1.2. Research and Development Clinical Studies
13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail
13.1.4. Tabulated Product Summary General Description Table
14. Opioid Dependence Key Companies15. Opioid Dependence Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Opioid Dependence Unmet Needs18. Opioid Dependence Future Perspectives19. Opioid Dependence Analyst Review20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aphios
  • Nicholson Science